乳腺癌诊断后多基因胚系测序的应用、结果与结局
该研究基于SEER登记处2013-2015年乳腺癌患者调查(n=5080),分析多基因测序对比BRCA1/2-only测序的应用趋势、检测结果及预防性乳房切除率。多基因测序比例从2013年25.6%升至2015年66.5%,致病性变异检出率提高约2倍,但未增加预防性乳房切除率;术后延迟检测和不确定性变异(VUS)的种族差异是待改进靶点。
要点
- 多基因测序快速取代BRCA1/2-only测序,2015年占比达66.5%。
- 多基因测序提高致病性变异检出率(高风险12% vs 7.8%;平均风险4.2% vs 2.2%)。
- 多基因测序未增加预防性乳房切除率,BRCA1/2致病性变异者切除率最高(79.0%)。
核心结论
- 多基因测序在社区实践中快速取代BRCA1/2-only测序,使临床相关致病性变异检出率提高2倍,且未增加预防性乳房切除。
- 术后延迟检测和VUS的种族差异是多基因测序临床效用需改进的重要靶点。
研究设计与样本
- 基于人群的回顾性队列研究,纳入2013年1月至2015年12月SEER登记处(佐治亚州和加州洛杉矶)诊断的乳腺癌患者,调查应答n=5080(应答率70%),最终分析5026例。
- 将调查应答与SEER数据及4家实验室的临床基因检测结果(BRCA1/2-only或多基因测序)链接。
主要发现
- 多基因测序率从2013年25.6%升至2015年66.5%,BRCA1/2-only测序从74.4%降至33.5%。
- 多基因测序更常由遗传咨询师开具(25.5% vs 15.3%),更常延迟至手术后(32.5% vs 19.9%)。
- 多基因测序提高任何致病性变异检出率:高风险患者12% vs 7.8%,平均风险患者4.2% vs 2.2%。
- 多基因测序增加VUS检出率,少数族裔更高:白人23.7% vs 2.2%,黑人44.5% vs 5.6%,亚裔50.9% vs 0%。
- 预防性乳房切除率未因多基因测序增加,BRCA1/2致病性变异者79.0%,其他致病性变异37.6%,VUS 30.2%,阴性35.3%。
临床怎么用
- 乳腺癌诊断后多基因测序可提高致病性变异检出,应关注检测时机(避免术后延迟)并规范遗传咨询。
- 对VUS尤其是少数族裔患者,需加强结果解读与随访管理,避免过度干预。
局限性
- 仅26.2%患者链接到基因检测结果,可能存在选择偏倚。
- 为观察性回顾性设计,无法确立因果关系。
- VUS分类可能随实验室和随时间变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Low-cost sequencing of multiple genes is increasingly available for cancer risk assessment. Little is known about uptake or outcomes of multiple-gene sequencing after breast cancer diagnosis in community practice. OBJECTIVE: To examine the effect of multiple-gene sequencing on the experience and treatment outcomes for patients with breast cancer. DESIGN, SETTING, AND PARTICIPANTS: For this population-based retrospective cohort study, patients with breast cancer diagnosed from January 2013 to December 2015 and accrued from SEER registries across Georgia and in Los Angeles, California, were surveyed (n = 5080, response rate = 70%). Responses were merged with SEER data and results of clinical genetic tests, either BRCA1 and BRCA2 (BRCA1/2) sequencing only or including additional other genes (multiple-gene sequencing), provided by 4 laboratories. MAIN OUTCOMES AND MEASURES: Type of testing (multiple-gene sequencing vs BRCA1/2-only sequencing), test results (negative, variant of unknown significance, or pathogenic variant), patient experiences with testing (timing of testing, who discussed results), and treatment (strength of patient consideration of, and surgeon recommendation for, prophylactic mastectomy), and prophylactic mastectomy receipt. We defined a patient subgroup with higher pretest risk of carrying a pathogenic variant according to practice guidelines. RESULTS: Among 5026 patients (mean [SD] age, 59.9 [10.7] years), 1316 (26.2%) were linked to genetic results from any laboratory. Multiple-gene sequencing increasingly replaced BRCA1/2-only testing over time: in 2013, the rate of multiple-gene sequencing was 25.6% and BRCA1/2-only testing, 74.4%; in 2015 the rate of multiple-gene sequencing was 66.5% and BRCA1/2-only testing, 33.5%. Multiple-gene sequencing was more often ordered by genetic counselors (multiple-gene sequencing, 25.5% and BRCA1/2-only testing, 15.3%) and delayed until after surgery (multiple-gene sequencing, 32.5% and BRCA1/2-only testing, 19.9%). Multiple-gene sequencing substantially increased rate of detection of any pathogenic variant (multiple-gene sequencing: higher-risk patients, 12%; average-risk patients, 4.2% and BRCA1/2-only testing: higher-risk patients, 7.8%; average-risk patients, 2.2%) and variants of uncertain significance, especially in minorities (multiple-gene sequencing: white patients, 23.7%; black patients, 44.5%; and Asian patients, 50.9% and BRCA1/2-only testing: white patients, 2.2%; black patients, 5.6%; and Asian patients, 0%). Multiple-gene sequencing was not associated with an increase in the rate of prophylactic mastectomy use, which was highest with pathogenic variants in BRCA1/2 (BRCA1/2, 79.0%; other pathogenic variant, 37.6%; variant of uncertain significance, 30.2%; negative, 35.3%). CONCLUSIONS AND RELEVANCE: Multiple-gene sequencing rapidly replaced BRCA1/2-only testing for patients with breast cancer in the community and enabled 2-fold higher detection of clinically relevant pathogenic variants without an associated increase in prophylactic mastectomy. However, important targets for improvement in the clinical utility of multiple-gene sequencing include postsurgical delay and racial/ethnic disparity in variants of uncertain significance.
引用
- Kurian AW, Ward KC, Hamilton AS, et al. Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer. JAMA Oncol. 2018. PMID: 29801090. doi:10.1001/jamaoncol.2018.0644
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。